Inhibition of Platelet Production Induced by an Antiplatelet Drug, Anagrelide, in Normal Volunteers

Summary

Administration of anagrelide, an antiplatelet agent, to ten normal male subjects was accompanied by an asymptomatic fall in platelet count. The drop was gradual and usually occurred within two weeks. Only a slight shortening of platelet survival was seen. Bone marrow morphology appeared normal. Measurement of platelet production rates showed a reduced response to thrombocytopenia. A substantial increase in the percentage of large platelets was observed in drug treated subjects. These observations are compatible with a selective inhibition of platelet production. Based upon these findings, the use of anagrelide will probably be best limited to short-term applications or to conditions where selective lowering of platelet count may be desired such as in polycythemia rubra vera or idiopathic thrombocytosis.

Key words

Antiplatelet agent - Platelet survival - Bone marrow - Thrombocytopenia

• References

• 1 Gangarosa EJ, Johnson TR, Ramos HS. Ristocetin-induced thrombocytopenia: Site and mechanism of action. Arch Intern Med 1960; 105: 107-113
• 2 Coblyn JS, Weinblatt M, Holdsworth D, Glass D. Gold-induced thrombocytopenia. Ann Intern Med 1981; 95: 178-181
• 3 Natelson EA, Lynch EC, Alfrey CP, Gross JB. Heparin-induced thrombocytopenia. Ann Intern Med 1969; 71: 1121-1125
• 4 Hackett T, Kelton JG, Powers P. Drug-induced platelet destruction. Semin Thromb Haemostas 1982; 8: 116-137
• 5 The Anturane Reinfarction Trial Research Group. Sulfinpyrazome in the prevention of sudden death after myocardial infarction. N Engl J Med 1980; 302: 250-302
• 6 Weiss HJ. Antiplatelet therapy (second of two parts). N Engl J Med 1978; 298: 1403-1406
• 7 Fleming JS, Buyniski JP, Cavanagh RL, Bierwagen ME. Pharmacology of a potent, new antithrombotic agent, 6-methyl- 1,2,3,5-tetrahydroimidazo (2,1-b) quinazolin-2-one hydrochloride monohydrate. J Pharmacol Exp Ther 1975; 194: 435-439
• 8 Fleming JS, Buchanan JO, Buyniski JP. The effect of a potent inhibitor of platelet aggregation, BL 3459, on adrenaline-induced myocardial necrosis in beagle dogs. Eur J Pharmacol 1976; 40: 57-62
• 9 Thomas LC, Giles TD, Stuckey WJ, Mautner RK, Iteld BJ. Racial differences in platelet survival time in patients with symptomatic coronary atherosclerosis. Arteriosclerosis 1983; 3: 138-140
• 10 Garg SK, Amorosi EL, Karpatkin S. Use of the megathrombocyte as an index of megakaryocyte number. N Engl J Med 1971; 284: 11-17
• 11 Harker LA, Finch CA. Thrombokinetics in man. J Clin Invest 1969; 48: 963-974
• 12 Lindenbaum J, Hargrove RL. Thrombocytopenia in alcoholics. Ann Intern Med 1968; 68: 526-532